Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06181227 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
A Phase 2 study, sponsored by Aviceda Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT06181227 is a Phase 2 study that was terminated before completion, run by Aviceda Therapeutics. The registered enrollment target is 21 participants.
The verdict
NCT06181227, a Phase 2 study, was terminated before completion, sponsored by Aviceda Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
Interventions
- DRUG AVD-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-11-30 |
| Est. Completion | 2024-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06181227
The ClinicalTrials.gov registry entry for NCT06181227 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aviceda Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVD-104 is the first listed.
NCT06181227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06181227 about?
NCT06181227 is a clinical study titled "A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema". A Phase 2 study to determine the safety and preliminary efficacy of intravitreal injections of AVD-104, a novel glyco-mimetic nanoparticle, in reducing macular edema associated with diabetic retinopathy.
What is the current status of trial NCT06181227?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2023-11-30. Estimated completion is 2024-04-05.
What interventions are being tested in trial NCT06181227?
The interventions under investigation include: AVD-104 (DRUG).
Who is sponsoring clinical trial NCT06181227?
This trial is sponsored by Aviceda Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.